Dravet Syndrome (DS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Dravet Syndrome (DS) Market Outlook

Thelansis’s “Dravet Syndrome (DS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dravet Syndrome (DS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dravet Syndrome (DS) Overview

Dravet syndrome, also known as Severe myoclonic epilepsy of infancy (SMEI), is a rare and fatal form of epilepsy that typically starts during childhood. Initial seizures are often prolonged, and other types develop in the second year of life. It is characterized by frequent, prolonged seizures that are often triggered by high body temperature (hyperthermia). Additionally, it presents with developmental delay, sleep disturbances, ataxia, hypotonia, speech problems, and other health issues. Approximately 85% of cases result from a mutation or deletion in the SCN1A gene (located at 2q24.3), which encodes a voltage-gated sodium channel. Most of these mutations are not inherited but may be part of a familial spectrum of genetic epilepsy known as febrile seizures-plus (GEFS+) in 5-10% of cases. About 5% of female cases might be attributed to mutations in the PCDH19 gene (located at Xq22.1). The cause is unknown in around 10% of cases. In about 3% of initially negative cases, somatic mosaic deletions or mutations in SCN1A can be found.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Dravet Syndrome (DS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034